|
Feb 17
|
Ironwood Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
|
|
Feb 16
|
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript
|
|
Feb 16
|
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
|
|
Feb 16
|
Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call
|
|
Feb 15
|
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
|
|
Feb 15
|
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
|
|
Jan 9
|
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
|
|
Jan 8
|
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
|
|
Dec 5
|
Shareholders have faith in loss-making Ironwood Pharmaceuticals (NASDAQ:IRWD) as stock climbs 9.7% in past week, taking five-year gain to 2.3%
|
|
Nov 30
|
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
|
|
Sep 12
|
Implied Volatility Surging for Ironwood (IRWD) Stock Options
|
|
Sep 7
|
Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?
|
|
Aug 12
|
Is There An Opportunity With Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 49% Undervaluation?
|
|
Aug 9
|
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
|
|
Aug 9
|
Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call
|
|
Aug 8
|
Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates
|
|
Aug 8
|
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
|